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Bladder cancer and arsenic through drinking water:
A systematic review of epidemiologic evidence
ELENI P. CHRISTOFORIDOU1, ELENA RIZA1, STEFANOS N. KALES2,
KONSTANTINOS HADJISTAVROU1, MELINA STOLTIDI1, ANASTASIA N. KASTANIA3
and ATHINA LINOS1
1Department of Hygiene, Epidemiology and Medical Statistics, Medical School of Athens, Athens, Greece
2Department of Environmental Health, Harvard School of Public Health, Cambridge, Massachusetts, USA
3Department of Informatics, Athens University of Economics and Business, Athens, Greece
Exposure to inorganic arsenic (As) through drinking water is a major international public health issue. We carried out a systematic
review of the existing literature examining the association between the risk of bladder cancer in humans and exposure to arsenic
through drinking water. We searched electronic databases for studies published from January 2000 up to April 2013. Eight ecological
studies, six case-control studies, four cohort studies and two meta-analyses were identified. The vast majority of the studies were
carried out in areas with high arsenic concentrations in drinking water such as southwestern and northeastern Taiwan, Pakistan,
Bangladesh, Argentina (Cordoba Province), USA (southeastern Michigan, Florida, Idaho) and Chile. Most of the studies reported
higher risks of bladder cancer incidence or mortality in areas with high arsenic concentrations in drinking water compared to the
general population or a low arsenic exposed control group. The quality assessment showed that among the studies identified, arsenic
exposure was assessed at the individual level only in half of them and only three assessed exposure using a biomarker. Further, five
out of eight ecological studies presented results with adjustment for potential confounders except for age; all cohort and case-control
studies presented results with adjustment for cigarette smoking status in the analysis. The majority of the studies with varying
study designs carried out in different areas provided evidence of statistically siginificant increases in bladder cancer risk at high
concentrations of arsenic (>50 µg L−1). Assessing bladder cancer risk at lower exposure concentrations requires further investigation.
Keywords: Arsenic, bladder cancer, drinking water, mortality, morbidity.
Introduction
Inorganic arsenic (As) is a naturally occurring metallic
element widely distributed in the earth’s crust.[1] Arsenic
occurs in drinking water through both natural and
anthropogenic sources. It occurs naturally in rock, soil
and sediment and these sources are particularly significant
determinants of regional levels of arsenic in ground and
surface water.[2] Arsenic is introduced into drinking-water
sources primarily through the dissolution of naturally
occurring minerals and ores.[3] Mining, smelting of non-
ferrous metals and burning of fossil fuels are the major in-
dustrial processes that contribute to anthropogenic arsenic
contamination of air, water and soil. Past use of arsenic-
containing pesticides, herbicides, insecticides, defoliants,
and soil biocides has led to agricultural land contamina-
Address correspondence to Eleni P. Christoforidou, Depart-
ment of Hygiene Epidemiology and Medical Statistics, Medical
School of Athens, M. Asias 75, 11527 Athens, Greece; E-mail:
echristof@med.uoa.gr
Received May 17, 2013.
tion.[2–4] The use of arsenic as a timber preservative and
in livestock feed additives has also resulted in additional
environmental contamination.[2–4] Arsenic has also been
found in herbal medicine products[5,6] and in tobacco with
an average concentration of about 1.5 µg per cigarette.[1]
The occurrence of arsenic in high concentrations in
drinking water has been recognized, over the past 30 years,
as a major public health concern in several areas world-
wide.[7–9] Throughout the world, more than 100 million
people are exposed through drinking water to arsenic at
concentrations greater than 50 µg L−1,[10] levels consid-
ered to be harmful to human health. While exposure to
such high concentrations is localized to specific regions[7]
(Table 1), exposure to lower, but still potentially harmful,
levels is evenmore widespread.[7,11] Argentina, Bangladesh,
India, Pakistan, Mexico, Mongolia, Germany, Thailand,
China, Chile, the United States, Canada, Hungary, Roma-
nia, Vietnam, Nepal, Myanmar and Cambodia are among
the countries where arsenic exists in varying concentrations
within groundwater.[7,12–14]
Setting regulations concerning arsenic concentrations in
drinking water has been a controversial issue.[15] It has been
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Table 1. Regions of the world with naturally elevated levels of
arsenic in groundwater.
Country/region Arsenic concentration (µg L−1)
Bangladesh <0.5–2,500
India/West Bengal <10–3,200
Viet Nam
China/Taiwan 10–1,820
China/Xinjiang, Shanxi 40–750
Thailand 1–5,000
Mongolia/Inner Mongolia <1–2,400
Argentina/Chaco-Pampean Plain <1–7,550
Northern Chile/Antofagasta 100–1,000
Bolivia
Mexico 8–620
Germany/Bavaria <10–150
Hungary, Romania/Danube Basin
Spain <1–100
Greece
Ghana <1–175
Canada/Moira Lake, Ontario 50–3,000
Canada/British Columbia 0.5–580
USA/Arizona <1,300
USA/California <1–2,600
USA/Nevada <2,600
Source: IARC.[7]
generally accepted that As concentrations ≥50 µg L−1 in
drinking water do not protect public health.[16] Even when
the concentration in drinking water is reduced to 10 µg L−1
according to the World Health Organization recommen-
dation,[17] potential cancer risks remain.[18] World Health
Organization Guidelines currently advise a concentration
of 10 µg L−1.[19] However, many developing countries still
have their standards set at 50 µg L−1. According to Coun-
cil Directive 98/83/EC in the European Union (EU), the
drinking water standard for arsenic is set at 10µg L−1.[20] In
2001, the government of USA reduced arsenic maximum
contaminant level (MCL) from 50 to 10 µg L−1. Table 2
shows elevated concentrations of arsenic in drinking wa-
ter from arsenic endemic areas around the world and the
respective current drinking water standards for arsenic in
each country.[7,21]
Ingested arsenic exposures can occur due to industrial
contamination, medicines or food. Worldwide, however,
the most common mode of exposure is through con-
sumption of groundwater containing naturally occurring
arsenic. Acute effects caused by the ingestion of inorganic
arsenic compounds are gastrointestinal damage, resulting
in severe nausea, vomiting and diarrhea, muscular cramps
and cardiac abnormalities. Shock can also develop rapidly
as a result of dehydration.[7] Acute, high-dose exposure
can lead to encephalopathy and peripheral neuropathy.[1]
Chronic arsenic exposure through drinking water has
been associated with Blackfoot disease, a severe form of
peripheral vascular disease, hypertension,[22,23] cardio-
vascular disease, cerebrovascular disease,[24,25] diabetes
Table 2. Arsenic contaminations in groundwater and population
at risk around the world.
Groundwater
Population concentrations Guidelines
Country/region at risk (µg L−1) (µg L−1)
Argentina 2 × 106 100–1,000 50
Bangladesh 5 × 107 <1–4,700 50
Bolivia 2 × 104 50
Chile 4.37 × 105 900–1,040 50
China, Inner Mongolia 6 × 105 1–2,400 50
China, Xinjiang
Province
1 × 105 1–8,000 50
Hungary 2.2 × 105 10–176 10
India, West Bengal 1 × 106 <10–3,900 50
Mexico 4 × 105 10–4,100 50
Nepal Unknown Up to 456 50
Peru 2.5 × 105 500 50
Romania 0.36 × 105 10–176 10
Taiwan 2 × 105 10–1,820 10
Thailand, Ronpibool 1 × 103 1–5,000 50
USA Unknown 10–48,000 10
Vietnam Millions 1–3,050 10
Canada 25
Australia 7
Laos 10
Brazil 50
Philippines and
Indonesia
50
Sri Lanka and
Zimbabwe
50
Bahrain, Egypt, Oman
and Saudi Arabia
50
Jordan and Syria 10
Japan 10
European Union Unknown 10
Source: Ng et al.,[21] IARC.[7]
mellitus, reproductive effects, respiratory disease and
long-term neurological effects such as peripheral neuropa-
thy.[1,4,7,18,26–29] Chronic exposure of humans to inorganic
arsenic in the drinking water has been also associated with
excess incidence of miscarriages, stillbirths, preterm births,
as well as infants with low birth weights.[1] Long-term
exposure to arsenic in drinking-water is causally related to
increased risks of skin, lung, liver, prostate, urinary bladder
and kidney cancer, as well as other skin changes such as hy-
perkeratosis and pigmentation changes.[4,7,18,26] Inorganic
arsenic compounds in drinking water are classified by the
International Agency for Research on Cancer (IARC) as
a Group 1 carcinogen (carcinogenic to humans).[3,7,30]
Major epidemiological studies of cancer in respect to
arsenic in drinking water include ecological studies and
fewer case-control and cohort studies. Many systematic
studies were conducted in various parts of the world
(Taiwan, Japan, Argentina, Chile, Mexico, USA, Europe,
Australia) regarding exposure to arsenic in drinking
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water and increased risks of urinary bladder, kidney,[31–52]
liver,[31–34,37,39–42,45,48–50,53] lung[31–34,37,39–42,45,46,48–50,53,54]
and skin cancer.[7,31–34,36,37,39,40,45,55–66] Concerning blad-
der cancer specifically, in the past 13 years a series of
epidemiological studies were conducted.[16,47,67–84]
Material and methods
Study search
We aimed to identify all studies assessing the association
between exposure to arsenic through drinking water and
bladder cancer. Using free text and key words (heavy met-
als, arsenic, drinking water, ingested water, potable water,
water ingestion, cancer, mortality, cohort study, case-
control study, ecological study), we searched the following
searchmachines: PubMed (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=PubMed), the Cochrane Library
(http://www.thecochranelibrary.com/view/0/index.html),
and TOXLINE (http://toxnet.nlm.nih.gov/) through
April 2013. In addition, we manually examined the
reference lists from related original research and review
articles or meta-analyses and documents (hand search).
All studies that were published up to April 2013 were
included as eligible for further evaluation.
Study selection
The following exclusion criteria were applied to the
abstracts identified in the literature search: (1) no original
data or new analysis (reviews, editorials); (2) studies not re-
ferring to the association between bladder cancer incidence
and/or mortality and arsenic in drinking water; (3) stu-
dies not involving humans; (4) not in English language;
(5) studies published before January 2000 and after April
2013 (6) studies that did not include measurements of
arsenic in drinking water and (7) case series and case
reports. We reviewed the full-text articles of all references
selected using the same criteria. After the full-text review,
references detailing observational studies (cohort, case-
control studies), descriptive studies (ecological studies) and
meta-analyses on the association between bladder cancer
risk and arsenic exposure through drinking water were
selected and examined so as to be included in this analysis.
We included both negative and positive studies. If different
reports from the same study were identified, the report with
the most updated information was included. Furthermore,
regarding duplicate publication, only one publication was
included. Two reviewers evaluated the eligibility of every
abstract or full-text article independently in a standardized
manner. The study selection process is shown in Figure 1.
Data abstraction and quality assessment
In order to assess the study quality, the included stud-
ies were catergorized according to the quality criteria of
Longnecker et al.[85] for observational studies (Table 3).
Results and discussion
Study selection
The search yielded 1,186 references (Fig. 1), of which 1,087
were excluded after abstract review as they did not ad-
dress the association between arsenic in drinking water and
cancer or they were case reports or case series or articles
published before January 2000 and after April 2013, not
in English language or with no full text available. Of the
99 articles obtained for full-text review, 74 pertained to ar-
senic exposure and cancer. We excluded 37 articles, as they
were reviews, editorials and documents-reports. Five arti-
cleswere also excluded as they only referred to arsenic expo-
sure and another two because they didn’t include measure-
ments of arsenic in drinkingwater. An additional 32 studies
were excluded because they referred to colon, prostate, kid-
ney, liver, lung, skin, childhood cancer or cancer in general.
One reference was excluded due to duplicate publication
and 2 because they were survival studies. This left 18 orig-
inal studies conducted in general populations and 2 meta-
analyses (Fig. 1) that met our inclusion criteria.
Study characteristics
Ecological studies. Eight out of the 20 studies included in
this analysis were ecological studies (Table 4). Of these, four
were conducted in high arsenic areas of USA,[67,68,70,78] two
in Taiwan,[16,84] one in Chile [71] and one in Argentina.[69]
All studies included both male and female participants.
Arsenic exposure was assessed either using grouped or eco-
logic measurements of drinking water concentrations (tap
or artesian well). All studies except three, compared age
standardized bladder mortality rates across geographic re-
gions or through time. Han et al.[70] calculated age-adjusted
incidence rate for cancers of the urinary bladder, kidney and
renal pelvis, liver and bile duct, lung and bronchus, non-
Hodgkin’s lymphoma (NHL), and all malignant cancers.
Nieder et al.[68] calculated bladder cancer Odds Ratio (OR)
(95% Confidence Interval [CI]) based on distance from the
well water arsenic exposure.[68] At last, Pou et al.[69] calcu-
lated bladder cancer age-standardized mortality rates con-
cerning low, intermediate and high level of arsenic exposure
(Table 4).
Cohort and case–control studies. Ten of the studies in-
cluded in this analysis were cohort or case-control studies
(Table 4). Of the six case-control studies, 3 were conducted
in USA,[72,74,82] one in Argentina,[73] one in Finland [83]
and one in Pakistan.[75] Of the four cohort studies, two
were conducted in Taiwan,[47,76] one in Denmark [77] and
one in Bangladesh.[79] All case-control studies had more
than 100 cancer cases.[72–75,82] Four case-control studies as-
sessed bladder cancer incidence among both males and
females.[72–74,82] The study of Wadhwa et al.[75] compared
As concentrations in whole blood and scalp hair samples
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Bladder cancer and arsenic through drinking water 1769
Fig. 1. Flow diagram of study selection process.
of exposed male patients with cancer and controls vs. non-
exposed male patients with cancer and controls. The study
of Michaud et al.[83] carried out in Finland estimated blad-
der cancer risk based on toenail arsenic level among male
smokers.[83] All case-control studies used community-based
controls. Three out of four cohort studies[47,76,77] assessed
urinary cancer (including bladder cancer) incidence, ex-
cept for Chen and Ahsan,[79] which measured lifetime mor-
tality risk from liver, bladder and lung cancer. Of all the
studies identified, only three assessed As exposure using a
biomarker, such as blood, scalp hair or toenails.[75,82,83]
Documentation of arsenic exposure through drinking
water was based on geographic or other ecologic or
grouped water measurements in most of the studies. The
study conducted in Michigan calculated arsenic exposure
by collecting water samples from sources used for drinking
(including coffee) and cooking, as well as untreated well
water in current residences of participants and by using a
geostatisticalmodel for predicting arsenic concentrations at
past residences on private well water.[74] Steinmaus et al.[72]
determined arsenic exposure for each subject by linking
each residence within the study area to a water arsenic
measurement for that residence. In this way, an arsenic con-
centration could be assigned to each year of a subject’s life
within the study area. In the study of Bates et al.[73] water
samples were collected from each subject’s current resi-
dence and as many of his or her residential sources within
the previous 40 years as practicable, particularly fromwells.
Historical records of arsenic content were also obtained
for community water supplies. Regarding the case-control
studies, in the investigation conducted in Pakistan, cases
(exposed) resided in villages of south western part of
Pakistan using surface and underground water, which
have had chronically high levels of As. The controls (non-
exposed) lived in big cities and drank municipal treated
water with low levels of As (<10 µg L−1) and smoked
branded cigarette containing low levels of As, as well.[75]
Of the cohort studies, the Chen et al.[76] study carried out
in northeastern Taiwan estimated arsenic concentrations
using water samples collected in the 85.1% households.
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1770 Christoforidou et al.
Similarly, in the second study conducted in northeast-
ern Taiwan well water samples were also collected from
85.1% of households during the home interview.[47] On the
other hand, arsenic concentrations in Danish drinking wa-
ter were taken from a database that developed from the
Geological Survey of Denmark and Greenland.[77,86] Fi-
nally, the Chen and Ahsan [79] study in Bangladesh used
water samples from 5,966 contiguous hand-pumped tube
wells tested for arsenic in 2000, in a well-defined geographic
area of Araihazar, Bangladesh.
Three of the cohort studies and all the case-control stud-
ies were based on incident bladder cancer cases.[47,72–77,82,83]
Only Chen and Ahsan [79] estimated excess lifetime risks
of death from bladder cancer using an exposure distri-
bution, death probabilities and cancer mortality rates
from Bangladesh and dose-specific relative risk estimates
from Taiwan.[79] In all case-control studies, there was
histopathological confirmation of the cancer diagnoses
for the cases.[72–75,82,83] In all cohort and case-control
studies there was at least adjustment for age. There were
other adjustment factors such as gender in eight stud-
ies,[47,72–74,76,79,82,83] smoking in seven studies,[47,72–74,76,77,82]
race in two studies,[72,74] education in five studies,[72–74,76,77]
income in one study,[72] alcohol consumption in two stu-
dies [76,77] and occupational exposure in three studies.[72,74,77]
Meta-analyses
The Chu and Crawford-Brown [80] meta-analysis estimated
the dose-response relationship between excess probabil-
ity of bladder cancer and arsenic intake by water inges-
tion combining seven epidemiologic studies of populations
from several regions such as Taiwan, the United States,
Argentina, Chile and Finland (case-control and cohort
studies)[43,44,46,47,72,73,87] exposed to low- and high-level of
arsenic through drinking water.
The Mink et al.[81] meta-analysis was based on eight
epidemiologic studies of populations from several regions
such as the United States, Argentina, Finland and north-
eastern Taiwan (case-control and cohort studies) exposed
to low levels of arsenic (<100–200µgL−1) throughdrinking
water [43,44,47,49,72,73,82,83] and evaluated the association be-
tween the risk of bladder cancer and low-level exposures to
arsenic through drinking water.
Quality assessment
When we rated the included studies using quality criteria,
the overall quality of evidence was considered to be high
(Table 3). Half of the studies assessed arsenic exposure in-
dividually.[47,68,72–74,76,77,79,82,83] Five out of eight ecological
studies used adjustments for other potential confounders
except for age.[68–71,84] All cohort and case-control studies
were adjusted for cigarette smoking status. Of all the
studies identified, only three assessed exposure using a
biomarker.[75,82,83]
Associations between arsenic and bladder cancer
Ecological studies
The Lamm et al.[67] study stratified analysis and regression
analyses (both unweighted and weighted by county pop-
ulation and using both mean and median arsenic concen-
trations) of the county-specific white male bladder cancer
mortality data (1950–1979) and county-specific groundwa-
ter arsenic concentration data (obtained for 133 U.S. coun-
ties known to be exclusively dependent on groundwater
for their public drinking water supply) found no arsenic-
related increase in bladder cancer mortality over the expo-
sure range of 3 to 60 µg L−1.
In the study conducted in Florida by Nieder et al.[68] ad-
vanced bladder cancer clusters had an increased likelihood
of being near known arsenic contaminated wells. Regard-
ing late stage bladder cancer, the OR was 1.4 (95% CI: 1.1,
1.8) for those living >3–5 miles from a drinking water well
and 2.0 (95% CI: 1.7, 2.5) for those living <3 miles from a
well known to be contaminated with arsenic.
Yang et al.[84] conducted a standardized mortality ra-
tio analysis for bladder cancer calculated for the Blackfoot
disease endemic area in Taiwan for the years 1971–2000 in
order to examine the hypothesis that bladder cancer mor-
tality decreased after installing a tap-water supply system,
which eliminated arsenic exposure through artesian well
water. During the period preceding tap-water installation,
the Standardized Mortality Ratio (SMR) for bladder can-
cer was markedly elevated for both men and women and
substantially higher in females (male: 215–1025, female:
763–2424). The results of the study showed that mortal-
ity from bladder cancer decreased gradually after installing
tap-water supply system that eliminated arsenic exposure
from artesian well water. This particular study strength-
ens the possibility that the observed association between
arsenic exposure and bladder cancer is causal.[84]
Consistent with the findings from a previous study
conducted in Co´rdoba (Argentina), where bladder can-
cer SMRs were consistently higher in counties with doc-
umented arsenic exposure (Hopenhayn-Rich et al.[38]), Pou
et al.[69] found that bladder cancer mortality rates tended
to increase with age, in a more strong and rapid way in
men, from 0.88 (95% CI 0.3, 2.4) to 91.1 (95% CI: 71.6,
115.9) for men, and from 0.36 (95% CI: 0.08, 1.72) to 31.6
(95% CI: 20.7, 48.2) for women, in both genders for the
5-year age groups from 37–42 to 82–87. The association
between bladder cancer, gender and exposure to arsenic
was confirmed. Relative Risk (RR) was higher among men
who were exposed to increasing As exposure categories.
RR for male at low exposure (0–40 µg L−1) was calculated
equal to 3.14, for male at intermediate exposure (40–320µg
L−1) 4.03 and for male at high exposure (320–1800 µg L−1)
4.71 versus female at low exposure. Given the magnitude of
the RRs and the precision of the estimates, the association
between exposure to arsenic through drinking water and
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Bladder cancer and arsenic through drinking water 1771
bladder cancer mortality increase is unlikely to be due to
confounding factors.
In the study conducted in Idaho by Yueh-Ying Han
et al.[70] female incidence rates for bladder cancer were
higher in the intermediate arsenic counties compared to
the low ones. The results did not show a dose-response
effect between arsenic levels in ground water and cancer
incidence. What is more, multivariate regression analysis
found that bladder cancer incidence was not associated
with ground water arsenic levels after adjusting for race,
gender, population density, smoking and body mass index
(BMI). Counties with a higher prevalence of current smok-
ing had a higher bladder cancer incidence (P = 0.024).
Female bladder cancer incidence rates were higher when
intermediate arsenic counties were compared to low ones.
Investigating bladder as well as lung cancer mortality for
the period 1950–2000, Marshall et al.[71] compared Chile’s
region II with region V. In region V drinking water was free
of arsenic while in region II during the period 1958–1970
the arsenic drinking water concentrations averaged 870 µg
L−1. After water treatment plants installation in the 1970s
arsenic concentrations in drinking water began to decline.
Elevated rate ratios in region II became apparent about
10 years after arsenic exposure increased, with a peak in
the years around 1990, and continued to be remarkably
increased up to the year 2000. The peak bladder cancer
RRs were calculated equal to 6.10 (95% CI: 3.97, 9.39) for
men and 13.8 (95% CI: 7.74, 24.5) for women. The patterns
of latency shown in this mortality study provide further
evidence for relationship of causality between arsenic in the
water and increased rates of bladder cancer since increased
rates of this type of cancer temporally followed the increase
in arsenic exposure in a plausible manner.
In the study carried out by Meliker et al.[78] the rela-
tionship between moderate drinking water arsenic levels
(mean arsenic concentration: 11 µg L−1) and selected dis-
ease outcomes concerning several types of cancer (includ-
ing bladder cancer), diseases of the respiratory and circu-
latory system, diabetes mellitus, liver and kidney diseases
was evaluated by conducting a SMR analysis in six coun-
ties in southeastern Michigan for the period 1979–1997.
For the whole of the six counties the mean and median ar-
senic concentrations (population-weighted) were 11.00 µg
L−1 and 7.58 µg L−1, respectively. Concerning bladder can-
cer, Meliker et al.[78] did not find an elevated bladder cancer
SMR (0.94 [95% CI 0.82, 1.08] for males and 0.98 [95% CI
0.80, 1.19] for female). In Taiwan, Morales et al.[16] found
no increase in bladder cancer mortality examining arsenic
exposure levels below 400 µg L−1.
Cohort studies
In an effort to explain the relationship between urinary
cancer and ingested arsenic in lower concentrations and to
evaluate the influence of duration, latency and recency of
these exposures, Chen et al.[76] conducted a cohort study
of 8,086 residents in the area of northeastern Taiwan for
12 years. On the whole, they observed 45 urinary cancers,
including 23 bladder cancers. An increasing risk of urinary
cancer was found in relation to increasing arsenic concen-
tration (P < 0.001). The age- and sex-adjusted RR (95%
CI) was calculated equal to 7.73 (2.69, 22.3) when exposure
to ≥300 µg L−1 was compared with <10 µg L−1. For those
exposed to high concentrations (>100 µg L−1), the relative
risks were greater than 5-fold, while the risk was increased
but not significant for low concentrations (<100 µg L−1).
What is more, comparing to subjects at low arsenic expo-
sure (<10 µg L−1) at enrollment, the subjects that drank
water from wells with higher concentrations (≥10 µg L−1)
since their birth (RR = 3.69; 95% CI: 1.31, 10.4) or still
drank at enrollment (RR = 3.50; 95% CI: 1.33, 9.22), or
drank for more than 50 years (RR = 4.12; 95% CI: 1.48,
11.5) had a significantly increased urinary cancer risk.
Similarly, Chiou et al.[47] found a significantly increased
incidence of urinary cancers (including 10 bladder cancer
cases) for those drinking As-contaminated water >100 µg
L−1 (with half of those residents having exposures over
300 µg L−1) when compared with the general population
in Taiwan (Standardized Incidence Ratio-SIR = 2.05; 95%
CI: 1.22, 3.24). The SIR for bladder cancer was 1.96 (95%
CI: 0.94, 3.61).
With the objective of determining if an increased risk
for bladder cancer is associated with exposure arsenic
through drinking water with low As concentrations (range:
0.05–25.3 µg L−1) in Denmark, Baastrup et al.[77] carried
out a prospective cohort study of 57,053 persons (214 cases)
in the areas of Copenhagen and Aarhus. No significant as-
sociation between exposure to arsenic at low levels and risk
for bladder cancer was found after adjustment for smoking
status, smoking duration, smoking intensity, education and
occupation. Specifically, the incidence RR for bladder can-
cer was 1.0 (95%CI: 0.93, 1.11) for a time-weighted average
exposure of 1.2 µg L−1, and 1.0 (95% CI: 0.98, 1.04) for a
cumulative exposure of 5 mg during the total observation
period (1970–2003).
At last, in order to estimate excess lifetime risks of death
from liver, bladder and lung cancer an exposure distribu-
tion, death probabilities and cancer mortality rates from
Bangladesh and dose-specific relative risk estimates from
Taiwan were used by Chen et al.[79] The study resulted in
an at least doubling of lifetime mortality risk from liver,
bladder and lung cancers (229.6 vs 103.5 per 100,000 pop-
ulation) in Bangladesh owing to arsenic in drinking water
(range: <50 µg L−1 – ≥599 µg L−1). Lifetime excess mor-
tality risks (per 100,000 population) from bladder cancer in
Bangladesh was calculated equal to 5.43 and 0.28 for male
and female respectively.
Case-control studies
In the case-control study of Steinmaus et al.[72] in seven
counties of western United States (181 cases diagnosed
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1772 Christoforidou et al.
during the period 1994 to 2000 and 328 age and gender
matched controls) no increased risks were observed for ar-
senic intake greater than 80 µg/day (OR = 0.94, 95% CI:
0.56, 1.57). However, when the analysis was focused on ex-
posures going back 40 or more years ago, an OR of 3.67
(95% CI: 1.43, 9.42) was found for arsenic intake greater
than 80 µg/day (median intake: 177 µg/day) in smokers.
They concluded that the results provided some evidence
that smokers who ingest water with arsenic at concentra-
tions close to 200 µg/day may be at increased risk of blad-
der cancer.
In Bates et al.[73] study in two Co´rdoba counties of
Argentina during 1996–2000 (114 case-control pairs,
matched on age, sex and county) no evidence of associ-
ations between bladder cancer incidence and exposure es-
timates based on arsenic concentrations in drinking water
were identified.However,whenwell-water consumptionper
se was used as the exposuremeasure, time-window analyses
provided the evidence that use of well water for more than
50 years before interview was associated with an increased
bladder cancer risk. This conclusion was limited to ever
smokers (OR= 2.5, 95% CI: 1.1, 5.5 for 51–70 years before
interview), without being able to exclude the possibility of
this result occurring due to chance.
In the study carried out byWadhwa et al.[75] in Pakistan,
they compared As in whole blood and scalp hair samples
from exposed male patients with lung or bladder cancer
and referents versus non-exposed lung or bladder male pa-
tients with cancer and referents. Concentrations of arsenic
in biological samples were clearly elevated in exposed male
(lung and bladder) cancer patients consuming drinking wa-
ter with high arsenic concentration when compared to can-
cer patients consumingmunicipal treated water of low level
of As and the exposed and unexposed referents, as well.
In the case-control study conducted by Meliker et al.[74]
in southeastern Michigan, the objective was to evaluate
the relationship between bladder cancer and arsenic
concentration between 10 and 100 µg L−1 in drinking
water for the period 2000–2004. Low-level time-weighted
average (TWA) arsenic concentration in drinking water
and arsenic intake were not associated with bladder cancer
when cases were compared with a control group exposed
to arsenic concentration <1 µg L−1 (OR = 1.10; 95%
CI: 0.65, 1.86). Even among ever-smokers, bladder cancer
risks for those exposed to arsenic level greater than 10 µg
L−1 were not elevated when compared to the control group
exposed to arsenic concentration <1 µg L−1 (OR = 0.94;
95% CI: 0.50, 1.78).
Similarly, in order to examine the effects of low to mod-
erate levels of arsenic exposure through water ingestion on
bladder cancer incidence in New Hampshire (USA), Kara-
gas et al.[82] conducted a case-control study for the period
July 1994–June 1998. In this area, As levels in private wells
are typically above 10 µg L−1. Arsenic exposure was as-
sessed at the individual level using toenail clippings as a
biomarker. An elevated odds ratio for bladder cancer was
found (OR: 2.17, 95% CI: 0.92, 5.11) when smokers with
greater than 0.330µg g−1 nailAswere compared to smokers
with less than 0.06 µg g−1 in their toenail. No association
between toenail As concentration and bladder cancer risk
was observed among never smokers.
In order to evaluate the relation between low exposure
to inorganic arsenic through drinking water (<100 µg L−1)
at the individual level and bladder cancer risk, Michaud
et al.[83] used arsenic toenail concentrations as a biomarker
in the context of a nested case-control study. The study in-
cluded 280 bladder cancer cases and 293 controls that were
all male smokers aged 50–69 and participants in the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study, a co-
hort study carried out in Finland for 14 years. ORs were
calculated using logistic regression analyses.No association
between bladder cancer risk and inorganic arsenic concen-
tration was noted when men with the highest arsenic con-
centrations in their toenail were compared with those with
the lowest: 1.13 (95% CI: 0.70, 1.81) for the highest quintile
versus 1.14 (95% CI: 0.52, 2.51) for the lowest quintile.
Meta-analyses
Assuming a linear dose-response association at all levels of
arsenic exposure, Chu and Crawford-Brown[80] used fixed-
effect and random-effect models in order to estimate the
averaged coefficient of the linear-logistic regression model
for the relationship between the excess probability of blad-
der cancer and the amount of arsenic intake. A homogene-
ity test was carried out, as well. Taking into account the
maximum contaminant level (MCL) of 10 µg L−1 the as-
sociated bladder cancer risk was estimated (at this MCL)
equal to 2.29 × 10−5. Chu et al.[80] meta-analysis produced
an aggregated dose-response model whose best estimate of
the slope factor was calculated equal to 3.0 × 10−5 (with
unit of probability per µg/kg/day), with the upper bound
of 1.27 × 10−4.
Using stratified analyses on smoking statusMink et al.[81]
evaluated the association between arsenic exposure in
drinking water at low concentrations and risk of bladder
cancer calculating summary relative risk estimates. They
also examined heterogeneity; study design and sample size
across studies and improved the precision of estimates.
They concluded that arsenic exposure at low concentrations
(<100–200 µg L−1) alone did not seem to be an important
independent risk factor for bladder cancer.
Conclusions
Based on a complete review of the international epidemi-
ologic evidence on the topic and following a systematic
review protocol, the present report found fairly consistent
evidence of an increased risk of bladder cancer incidence
and mortality in association with high concentrations
of arsenic in drinking water (>50 µg L−1). Considerable
uncertainty remains about the bladder cancer risks at
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Table 5. Overall results from the original studies with arsenic
measurements in drinking water (µg L−1).
Arsenic concentration
level in drinking water
(µg L−1)
Number of
studies with
positive result
Number of
studies with
negative result
Mortality SMR or Lifetime
mortality risk >1
SMR or Lifetime
mortality risk <1
≤10 1 3
11–50 2 2
51–100 3 2
101–250 2 2
251–500 2 1
>500 2 1
Lamm et al.,[67] Pou et al.,[69] Morales et al.,[16] Meliker et al.[78]
and Chen et al.[79]
Incidence RR or OR>1 RR or OR<1
≤10 4
11–50 1 3
51–100 2 1
101–250 1 1
251–500 1 1
>500
Yueh-Ying Han et al.,[70] Bates et al.,[73] Meliker et al.,[74] Chen et al.,[76]
Chiou et al.[47] and Baastrup et al.[77]
lower concentrations of arsenic (<50 µg L−1) in drinking
water, which requires further investigation.
It was notable that among the case-control studies we
evaluated, an increased bladder cancer risk with As in
drinking water was only observed among smokers. In
Table 5, overall findings from the original studies that con-
tain arsenic measurements in drinking water (µg L−1) are
shownproviding the number of studieswith positive or neg-
ative results categorized by the level of exposure to arsenic
through drinking water. It is clear that at exposure levels
above 50 µg L−1, more studies found positive results (con-
cerning both bladder cancer mortality and incidence) than
negative ones. Although there were some methodologic
limitations in the included studies, the fairly consistent ob-
servations of statistically significant associations from the
majority of studies, at higher levels of exposure across
varying study designs carried out in different areas, provide
support for a causal association between ingesting drinking
water with concentrations of arsenic >50 µg L−1 and
bladder cancer risk. Bladder cancer risk at lower exposure
concentrations requires further investigation taking into
account smoking as well as other probable confounding
factors such as occupational exposure, age, gender, and
race.
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